Gilead Sciences, Inc.

Christopher J Swank

Scott D Schroeder

Eda Y Canales

Stephen E Ammann

Weng K Chang

Henok H Kinfe

Scott E Lazerwith

Devan Naduthambi

Michael R Mish

Gregory F Chin

Joshua J Van Veldhuizen

Jason K Perry

Xinpei Cai

Kevin X Rodriguez

Jessica L McKinley

Michael L Mitchell

Yasamin Moazami

Daniel G Shore

The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.

Sars-cov2 main protease inhibitors

SARS-COV2 main protease inhibitors

The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.

Thienopyrrole compounds

Growing community of inventors

San Mateo, CA, United States of America

Christopher J Swank